NASDAQ:RNXT RenovoRx (RNXT) Stock Price, News & Analysis $0.91 -0.02 (-1.80%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$0.86 -0.05 (-5.85%) As of 05:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About RenovoRx Stock (NASDAQ:RNXT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RenovoRx alerts:Sign Up Key Stats Today's Range$0.88▼$0.9450-Day Range$0.78▼$0.9952-Week Range$0.70▼$1.45Volume169,900 shsAverage Volume199,068 shsMarket Capitalization$41.15 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingModerate Buy Company Overview RenovoRx, Inc. is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers. RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors. By leveraging a patented catheter design, the system enables localized drug perfusion through arterial infusion, potentially enhancing tumor uptake of chemotherapeutic agents. RenovoRx has also entered strategic collaborations to advance its clinical programs, including licensing arrangements for development and commercialization in select international markets. Headquartered in Little Silver, New Jersey, RenovoRx conducts its clinical development activities through a network of investigative sites across the United States. The company’s management team comprises seasoned professionals with experience in interventional oncology, medical device development and regulatory affairs. As a Nasdaq-listed entity trading under the symbol RNXT, RenovoRx continues to advance its pipeline toward pivotal studies with the goal of offering new treatment options for patients with limited therapeutic alternatives.AI Generated. May Contain Errors. Read More RenovoRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreRNXT MarketRank™: RenovoRx scored higher than 82% of companies evaluated by MarketBeat, and ranked 99th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingRenovoRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialRenovoRx has a consensus price target of $8.50, representing about 830.6% upside from its current price of $0.91.Amount of Analyst CoverageRenovoRx has only been the subject of 2 research reports in the past 90 days.Read more about RenovoRx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for RenovoRx are expected to grow in the coming year, from ($0.31) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RenovoRx is -2.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RenovoRx is -2.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRenovoRx has a P/B Ratio of 6.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about RenovoRx's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.85% of the float of RenovoRx has been sold short.Short Interest Ratio / Days to CoverRenovoRx has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RenovoRx has recently decreased by 0.98%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRenovoRx does not currently pay a dividend.Dividend GrowthRenovoRx does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment1.40 News SentimentRenovoRx has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for RenovoRx this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for RNXT on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows2 people have added RenovoRx to their MarketBeat watchlist in the last 30 days. Company Ownership3.2 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $19,750.00 in company stock, which represents 0.0480% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, RenovoRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,750.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders9.40% of the stock of RenovoRx is held by insiders.Percentage Held by Institutions3.10% of the stock of RenovoRx is held by institutions.Read more about RenovoRx's insider trading history. Receive RNXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNXT Stock News HeadlinesRenovoRx Stock Short Interest Report | NASDAQ:RNXT | BenzingaJuly 7, 2026 | benzinga.comRenovoRx Stockholders Approve Directors and Equity PlanJune 30, 2026 | tipranks.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.July 14 at 1:00 AM | Profits Run (Ad)RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 TranscriptJune 23, 2026 | seekingalpha.comRenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic CancerJune 11, 2026 | globenewswire.comAscendiant Remains a Buy on RenovoRx (RNXT)June 5, 2026 | theglobeandmail.comRenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rdJune 4, 2026 | globenewswire.comRenovoRx, Inc.: RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic CancerMay 28, 2026 | finanznachrichten.deSee More Headlines RNXT Stock Analysis - Frequently Asked Questions How have RNXT shares performed this year? RenovoRx's stock was trading at $0.8401 at the beginning of 2026. Since then, RNXT stock has increased by 8.7% and is now trading at $0.9134. How were RenovoRx's earnings last quarter? RenovoRx, Inc. (NASDAQ:RNXT) announced its quarterly earnings results on Thursday, May, 14th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). The business earned $0.56 million during the quarter, compared to the consensus estimate of $0.47 million. RenovoRx had a negative net margin of 823.98% and a negative trailing twelve-month return on equity of 135.03%. Read the conference call transcript. When did RenovoRx IPO? RenovoRx (RNXT) raised $18 million in an initial public offering (IPO) on Thursday, August 26th 2021. The company issued 1,800,000 shares at a price of $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO. How do I buy shares of RenovoRx? Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of RenovoRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that RenovoRx investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), Bakkt (BKKT), NIO (NIO) and Phunware (PHUN). Company Calendar Last Earnings5/14/2026Today7/13/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (9m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 RNXT's financial health is in the Yellow zone, according to TradeSmith. RNXT has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNXT CIK1574094 Webwww.renovorx.com Phone650-284-4433Fax650-397-4433Employees6Year Founded2012Price Target and Rating Average Price Target for RenovoRx$8.50 High Price Target$14.00 Low Price Target$3.00 Potential Upside/Downside+830.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.17 million Net Margins-823.98% Pretax Margin-823.98% Return on Equity-135.03% Return on Assets-101.92% Debt Debt-to-Equity RatioN/A Current Ratio7.15 Quick Ratio6.95 Sales & Book Value Annual Sales$1.12 million Price / Sales36.74 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book6.09Miscellaneous Outstanding Shares45,050,000Free Float40,818,000Market Cap$41.15 million OptionableNot Optionable Beta0.99 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:RNXT) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour money is changingPorter Stansberry - who warned readers about Fannie Mae in 2006, called gold in 2008, and predicted COVID-era ...Porter & Company | SponsoredThe $5 company SpaceX can’t survive withoutThe investors who got rich on AI didn't all buy Nvidia. Some bought ASML, the company that makes the machines ...Traders Agency | SponsoredTrump Set to Unleash 219-Year-Old “Super Weapon” on U.S. SoilFour-time U.S. Presidential advisor Jim Rickards is warning of a political move he calls 'The Trump Supremacy'...Paradigm Press | Sponsored60 years. Zero competitors.One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 ti...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RenovoRx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
